No Data
No Data
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10
Eledon Pharmaceuticals' Tegoprubart: A Strong Buy Based on Industry-Wide Validation and Promising Drug Data
Express News | Eledon Pharmaceuticals - Sales Agreement Prospectus Covering Offering of up to $75 Mln Common Stock That May Be Issued Under Sales Agreement
Express News | Eledon Pharmaceuticals Inc Files for Mixed Shelf of up to $250 Mln – SEC Filing
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Opthea Limited Sponsored ADR (OPT)